GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Price-to-Free-Cash-Flow

Cellectis (Cellectis) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Price-to-Free-Cash-Flow?

As of today (2024-04-25), Cellectis's share price is $2.49. Cellectis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.25. Hence, Cellectis's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Cellectis's Price-to-Free-Cash-Flow or its related term are showing as below:

CLLS's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.19
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Cellectis's Free Cash Flow per Share for the three months ended in Sep. 2023 was $-0.31. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.25.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -2.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -10.30% per year.

During the past 13 years, Cellectis's highest 3-Year average Free Cash Flow per Share Growth Rate was 73.70% per year. The lowest was -315.10% per year. And the median was -11.50% per year.


Cellectis Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cellectis's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Price-to-Free-Cash-Flow Chart

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectis's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Cellectis's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cellectis's Price-to-Free-Cash-Flow falls into.



Cellectis Price-to-Free-Cash-Flow Calculation

Cellectis's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.49/-1.245
=N/A

Cellectis's Share Price of today is $2.49.
Cellectis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.25.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cellectis  (NAS:CLLS) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cellectis Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cellectis's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus